Research Genetic Cancer Center takes each cell sample and administers a single dose of Salicinium then measures apoptosis 48 hours later. The results are provided below. In practice Salicinium when taken every day builds up within the tissues and so apoptosis is continuing on a daily basis.


BioFocus Labs Cellular NK test measures the percentage of lysis or the killing capacity of the immune cells, the results are also provided below.


R.G.C.C.

BioFocus Labs Germany Cellular NK test results

                                                                    BIFOCUS LABS:

Immune-stimulative effect of Salicinium on immune-cells from cancer patients

Dr. Lothar Prix, Biofocus GmbH, Recklinghausen, Germany. www.biofocus.de


Methods:   Immune cells were obtained from blood samples of nine cancer patients. The capability of these immune cells to kill tumor cells in vitro was determined by using a cellular NK-test (Neri et al, Clin Diagn Lab Immunol. 2001 November; 8(6): 1131–1135). The basal killing activity was compared to the killing activity after treatment of the immune cells with Salicinium and the mistletoe extract Lektinol.    


Results:    

Patient #         basal killing activity       additional killing actitivty (%)        additional killing activity (%)

                                       (% of lysis)               after treatment with Salicinium         after treatment with Lektinol

  1                               7                                                28                                              11

  2                              17                                               17                                              15

  3                              14                                               31                                               8

  4                              34                                                6                                               28

  5                              37                                                3                                               10

  6                              13                                               41                                              36

  7                               9                                                21                                              18

  8                              31                                               32                                              46

  9                               9                                                39                                              15   


*** Patients 4 and 5 were control samples with no tumor***